{"id":{"repo_id":"vcu","oai_identifier":"oai:scholarscompass.vcu.edu:etd-2165"},"canonical_url":"https://search.dev.ndltd.org/etd/vcu/oai:scholarscompass.vcu.edu:etd-2165","repository":{"repo_id":"vcu","name":"Virginia Commonwealth University","base_url":"https://scholarscompass.vcu.edu/do/oai/"},"display":{"title":"Dual Mechanism Analgesia-Enhancing Agents","abstract":"Currently, there is an increasing need for novel analgesics that are potent but lack undesired side effects. Recent studies have shown that both 5-HT3 receptors and &#945;2B- adrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a high-affinity both for 5-HT3 and &#945;2B- adrenoceptors and could be viewed as the first example of a rather selective 5-HT3/&#945;2B- adrenoceptor ligand. MD-354, inactive by itself, potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tail- flick assay. An attempt to determine the underlying mechanism of this potentiating effect was the purpose of the present investigation. The studies focused on an examination of: i) MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tail-flick assay, iii) various analogs of MD-354 with different binding profiles in both mouse tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and &#945;2B- adrenoceptors are playing a role in the potentiation of clonidine analgesia by arylguanidines such as MD-354. Arylguanidines might represent a unique class of analgesia-enhancing agents with a dual (5-HT3/&#945;2- adrenoceptor) mechanism of action.","abstract_html":"Currently, there is an increasing need for novel analgesics that are potent but lack undesired side effects. Recent studies have shown that both 5-HT3 receptors and &amp;#945;2B- adrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a high-affinity both for 5-HT3 and &amp;#945;2B- adrenoceptors and could be viewed as the first example of a rather selective 5-HT3/&amp;#945;2B- adrenoceptor ligand. MD-354, inactive by itself, potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tail- flick assay. An attempt to determine the underlying mechanism of this potentiating effect was the purpose of the present investigation. The studies focused on an examination of: i) MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tail-flick assay, iii) various analogs of MD-354 with different binding profiles in both mouse tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and &amp;#945;2B- adrenoceptors are playing a role in the potentiation of clonidine analgesia by arylguanidines such as MD-354. Arylguanidines might represent a unique class of analgesia-enhancing agents with a dual (5-HT3/&amp;#945;2- adrenoceptor) mechanism of action.","abstract_has_math":false,"creators":["Young, Shawquia Elithia"],"institution":null,"degree_name":"Master of Science","degree_level":"Thesis","degree_discipline":"Medicinal Chemistry","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2005,"date_issued":"2005-01-01T08:00:00Z","date_published":"2005-01-01T08:00:00Z","updated_at":"2026-07-24T05:54:53Z","subjects":["ligands","antinociception","side effects","receptor","behavior","Chemicals and Drugs","Medicine and Health Sciences"],"languages":[],"rights":["© The Author"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholarscompass.vcu.edu/etd/1166"],"render_values":[{"text":"https://scholarscompass.vcu.edu/etd/1166","href":"https://scholarscompass.vcu.edu/etd/1166","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.25772/82RW-BZ86","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Young, Shawquia Elithia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2014-07-09T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medicinal Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["ligands","antinociception","side effects","receptor","behavior","Chemicals and Drugs","Medicine and Health Sciences"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["© The Author"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://doi.org/10.25772/82RW-BZ86","https://scholarscompass.vcu.edu/etd/1166"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Currently, there is an increasing need for novel analgesics that are potent but lack undesired side effects. Recent studies have shown that both 5-HT3 receptors and &#945;2B- adrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a high-affinity both for 5-HT3 and &#945;2B- adrenoceptors and could be viewed as the first example of a rather selective 5-HT3/&#945;2B- adrenoceptor ligand. MD-354, inactive by itself, potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tail- flick assay. An attempt to determine the underlying mechanism of this potentiating effect was the purpose of the present investigation. The studies focused on an examination of: i) MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tail-flick assay, iii) various analogs of MD-354 with different binding profiles in both mouse tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and &#945;2B- adrenoceptors are playing a role in the potentiation of clonidine analgesia by arylguanidines such as MD-354. Arylguanidines might represent a unique class of analgesia-enhancing agents with a dual (5-HT3/&#945;2- adrenoceptor) mechanism of action."]},{"key":"dc:title","label":"Title","values":["Dual Mechanism Analgesia-Enhancing Agents"]}]}],"canonical_facts":{"dc:creator":["Young, Shawquia Elithia"],"dc:date.available":["2014-07-09T07:00:00Z"],"dc:description.abstract":["Currently, there is an increasing need for novel analgesics that are potent but lack undesired side effects. Recent studies have shown that both 5-HT3 receptors and &#945;2B- adrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a high-affinity both for 5-HT3 and &#945;2B- adrenoceptors and could be viewed as the first example of a rather selective 5-HT3/&#945;2B- adrenoceptor ligand. MD-354, inactive by itself, potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tail- flick assay. An attempt to determine the underlying mechanism of this potentiating effect was the purpose of the present investigation. The studies focused on an examination of: i) MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tail-flick assay, iii) various analogs of MD-354 with different binding profiles in both mouse tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and &#945;2B- adrenoceptors are playing a role in the potentiation of clonidine analgesia by arylguanidines such as MD-354. Arylguanidines might represent a unique class of analgesia-enhancing agents with a dual (5-HT3/&#945;2- adrenoceptor) mechanism of action."],"dc:identifier":["https://doi.org/10.25772/82RW-BZ86","https://scholarscompass.vcu.edu/etd/1166"],"dc:rights":["© The Author"],"dc:subject":["ligands","antinociception","side effects","receptor","behavior","Chemicals and Drugs","Medicine and Health Sciences"],"dc:title":["Dual Mechanism Analgesia-Enhancing Agents"],"thesis:degree_discipline":["Medicinal Chemistry"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T05:54:53Z"}